1, global HCV infection is about 2.8%, about 185 million, the annual death cases due to HCV infection month 350,000 cases. 2006 national sero-epidemiological survey shows that the prevalence of anti-HCV in people aged 1-59 years old in China is 0.43%, plus the HCV infection in high-risk groups and high-incidence areas, about 10 million cases. Among them, HCV genotypes 1b and 2a are more common, with type 1b predominant (56.8%). The IL-28B genotype of HCV-infected patients in China is dominated by rs12979860 CC (84.1%). 2, Screening and management of people at high risk of hepatitis C according to the health industry standard of the People’s Republic of China “Screening and management of viral hepatitis C” promulgated by the National Health Planning Commission in July 2014. 3, Cirrhosis and HCC are the leading causes of death in patients with chronic hepatitis C. The annual incidence of cirrhosis with loss of compensation is 3% to 4%. Once cirrhosis occurs, the 10-year survival rate is about 80%; if decompensation occurs, the 10-year survival rate is only 25%; HCC has a 33% chance of death in the first year after diagnosis. 4, laboratory tests for hepatitis C updated. Antibody testing: Anti-HCV tests are available for screening of HCV-infected patients. Rapid diagnostic tests (RDTs) can be used to initially screen for anti-HCV. for those with positive antibodies, further screening for HCV RNA should be performed. HCV-RNA quantification: HCV RNA quantification should be performed by a PCR-based amplification method with high sensitivity and accuracy and a wide range of detection, with results expressed in IU/ml. Antigen testing: In the absence of HCV RNA testing conditions, HCV core antigen testing can be considered. (This article differs from European and American guidelines). Also perform HCV genotyping and HCV resistance-related gene testing, as well as host IL28B genotyping 5. For the non-invasive diagnosis of liver fibrosis in patients with hepatitis C. Recommendation 1: Non-invasive diagnostic imaging methods such as serology and/or transient elastography can be used to help determine the presence of cirrhosis or liver fibrosis in hepatitis C. Current noninvasive methods have better diagnostic efficacy for cirrhosis than for significant liver fibrosis. (A1). Recommendation 2: The combination of serology and noninvasive imaging indices such as transient elastography may improve the diagnostic accuracy of significant liver fibrosis. When the two results are inconsistent, liver biopsy is recommended to clarify the diagnosis. (A1) 6. Hepatitis C treatment goals. The goals of antiviral therapy are to clear HCV, obtain a cure, clear or reduce HCV-related liver damage, stop progression to cirrhosis, decompensated cirrhosis, liver failure or hepatocellular carcinoma, improve the long-term survival of patients, and improve the quality of life of patients. The clearance of HCV in patients with progressive liver fibrosis and cirrhosis can reduce the occurrence of cirrhotic decompensation, which can reduce but not prevent the occurrence of HCC and requires long-term monitoring of the occurrence of hepatocellular carcinoma. The clearance of HCV in patients with decompensated cirrhosis has the potential to reduce the need for liver transplantation, and the impact on the medium- and long-term survival of this group of patients needs further study. Pre-transplant antiviral therapy in liver transplant patients can improve liver function before transplantation and prevent reinfection after transplantation, and post-transplant antiviral therapy can improve the survival rate. 7. Hepatitis C antiviral drug recommendation. All HCV RNA-positive patients should receive antiviral therapy as long as they are willing to be treated and have no contraindications to treatment.PR regimen is the main regimen of antiviral therapy for patients with current HCV infection in China at this stage and can be applied to patients with all genotypes of HCV infection and no contraindications to treatment. DAA-based antiviral regimens include DAA combined with PR, DAA combined with ribavirin, and different DAA combinations or combinations, and the three regimens can cover almost all types of HCV-infected patients. Even if medical resources are limited, the decision to prioritize patients receiving antiviral therapy should be based on consideration of patient wishes, disease and drug accessibility. 8. Evaluation and monitoring of antiviral therapy for hepatitis C. Once the diagnosis of chronic hepatitis C is confirmed and HCV RNA is detected in the blood, standardized antiviral therapy should be administered. Before treatment, a comprehensive assessment should be made based on viral load, genotyping, liver fibrosis stage, and the presence of contraindications to antiviral therapy. (A1) Treatment should be individualized according to the on-treatment viral response during receipt of PEG-IFNα in combination with ribavirin. HCV RNA should be assessed before treatment, at 4 weeks, 12 weeks and 24 weeks of treatment using highly sensitive methods to assess viral response to guide treatment. (B1) Regardless of genotype, consider discontinuing the drug if HCV RNA decreases <2 log at 12 weeks of treatment or remains detectable at 24 weeks.